(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 24.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.51%.
Regenxbio's revenue in 2026 is $174,482,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $11,440,086,174, with the lowest RGNX revenue forecast at $8,649,708,548, and the highest RGNX revenue forecast at $20,724,841,628. On average, 13 Wall Street analysts forecast RGNX's revenue for 2027 to be $14,541,385,934, with the lowest RGNX revenue forecast at $4,503,948,064, and the highest RGNX revenue forecast at $29,009,497,224.
In 2028, RGNX is forecast to generate $23,171,950,656 in revenue, with the lowest revenue forecast at $11,733,184,746 and the highest revenue forecast at $41,518,997,108.